FDA "Approvables" Could Be Crawford's First Approval Challenge At FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA's backlog of 51 pending "approvable" NDAs and supplemental NDAs will provide one quantifiable marker to use in measuring the impact of a commissioner appointment.
You may also be interested in...
NDAC Member Wood Joins FDA Commissioner Candidate List
FDA Nonprescription Drug Advisory Committee member and Vanderbilt University Vice Chancellor Alastair Wood, MD, is one of several new candidates for FDA commissioner being considered by the White House
FDA Preparing For Crawford? Lumpkin Named Acting Deputy Commissioner
The appointment of former Office of Review Management Director Murray Lumpkin, MD, as acting deputy commissioner makes him the agency's highest ranking physician.
FDA "National Security" Mission: Counterfeiting And Bioterrorism?
FDA should heighten its focus on product security to ensure counterfeiting does not take place, not only for consumer safety, but to cut off a source of income for terrorists, asserted House Energy & Commerce Committee Senior Counsel Alan Slobodin.